Lupin gets final nod from USFDA for birth control pill
New Delhi : Drug firm Lupin BSE -4.32 % has received final approval from the US health regulator for marketing Norgestimate and Ethinyl Estradiol tablets, used for prevention of pregnancy, in the US market.
The company has received final approval from the United States Food and Drug Administration (USFDA) to market its Norgestimate and Ethinyl Estradiol tablets USP, 0.25 mg/0.035 mg, Lupin said in a filing to BSE.
The company's product is a generic version of Janssen Pharmaceuticals Inc's Ortho-Cyclen 28 tablets, it added.
"The approved product will be manufactured at Lupin's Pithampur facility," the company said.
Ortho-Cyclen tablets had US sales of USD 178.2 million as per IMS MAT June 2016 data, it added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd